GlassScriptPhysician profile
William Fielding
NPI 1154345015
$2,387.49
in general payments reported to CMS, 2019-2025
16 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $668 · 2024: $1,148 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.49 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.64 | 2023-2025 | |
| Novo Nordisk INC | $497.12 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $235.42 | 2023-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $221.06 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $149.12 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $133.59 | 2023-2024 | Veozah |
| Amgen INC. | $103.86 | 2024-2025 | Otezla, Repatha, Krystexxa |
| Dexcom, INC. | $86.49 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $83.78 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $75.16 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $72.63 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $52.11 | 2023-2024 | Farxiga |
| Idorsia Pharmaceuticals US INC | $35.83 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $27.02 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.40 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $19.26 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Fielding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.